09 Jun 2026 by admin in UncategorizedComments Windward Bio Doses First Patients in Phase 2 SIRIUS COPD Study of Ultra Long- Acting Anti-TSLP Antibody WIN378
08 Jun 2026 by admin in UncategorizedComments OriCell’s GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
08 Jun 2026 by admin in UncategorizedComments China NMPA Grants IND Clearance to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for the Treatment of Late-Stage Solid Tumors, Including Prostate Cancer
04 Jun 2026 by admin in UncategorizedComments Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
01 Jun 2026 by admin in UncategorizedComments Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
29 May 2026 by admin in UncategorizedComments Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
28 May 2026 by admin in UncategorizedComments Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study
28 May 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Submision of Biologics License Aplication (BLA) to U.S. FDA for Obexelimab in IgG4-RD FDA for Obexelimab in IgG4-RD
18 May 2026 by admin in UncategorizedComments Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
06 May 2026 by admin in UncategorizedComments Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia
05 May 2026 by admin in UncategorizedComments Sail Biomedicines Appoints Gene Marcantonio, M.D., Ph.D., as Chief Medical Officer
04 May 2026 by admin in UncategorizedComments Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long- Acting Immunology Therapies With Best-in-Disease Potential
04 May 2026 by admin in UncategorizedComments NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
28 Apr 2026 by admin in UncategorizedComments Avenzo Therapeutics Advances the Combination of CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) in Ongoing Phase 1/2 ORION-1 Study in HR+/HER2- Breast Cancer
22 Apr 2026 by admin in UncategorizedComments Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
14 Apr 2026 by admin in UncategorizedComments Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
10 Apr 2026 by admin in UncategorizedComments Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
07 Apr 2026 by admin in UncategorizedComments NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
27 Mar 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Pricing of Concurent Public Oferings of 2.50% Convertible Senior Notes Due 2032 and Comon Stock with Agregate Gros Proceds of $30.0 Milion Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
23 Mar 2026 by admin in UncategorizedComments Tempest Therapeutics Announces Up To $6 Million Private Placement
18 Mar 2026 by admin in UncategorizedComments Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
11 Mar 2026 by admin in UncategorizedComments Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
23 Feb 2026 by admin in UncategorizedComments Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
11 Feb 2026 by admin in UncategorizedComments Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
09 Feb 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Late-Breaking Platform Presentation of Results from Phase 2 MonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
12 Jan 2026 by admin in UncategorizedComments Oricell Therapeutics Announces $70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies
05 Jan 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Imunoglobulin G4-Related Disease (IgG4-RD) Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
21 Dec 2025 by admin in UncategorizedComments Windward Bio Expands Immunology Pipeline With WIN027, a Long-Acting, Clinical-Stage Bispecific Targeting TSLP and IL-13
15 Dec 2025 by admin in UncategorizedComments Zenas BioPharma’s Partner, InoCare Pharma, Anounces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
26 Nov 2025 by admin in UncategorizedComments Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
24 Nov 2025 by admin in UncategorizedComments Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin
19 Nov 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer
17 Nov 2025 by admin in UncategorizedComments NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
23 Oct 2025 by admin in UncategorizedComments Sail Biomedicines Appoints Martin Mackay, Ph.D., to Its Board of Directors
16 Oct 2025 by admin in UncategorizedComments NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
16 Oct 2025 by admin in UncategorizedComments Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment- Refractory Rheumatoid Arthritis (RA)
08 Oct 2025 by admin in UncategorizedComments Zenas BioPharmand InoCare Pharma Anounce License Agrement Granting Zenas Rights for Thre Autoimune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
07 Oct 2025 by admin in UncategorizedComments Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
22 Sep 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces $60 Million Series B Financing
